US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NanoViricides

1.59

-0.0900-5.36%

Volume:399.68K

Turnover:641.52K

Market Cap:27.72M

PE:-2.54

High:1.68

Open:1.61

Low:1.55

Close:1.68

52wk High:2.23

52wk Low:0.9400

Shares:17.43M

Float Shares:16.86M

Volume Ratio:0.66

T/O Rate:2.37%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6263

EPS(LYR):-0.6263

ROE:-99.75%

ROA:-55.39%

PB:3.69

PE(LYR):-2.54

Loading ...

Overview Company News Filings

NanoViricides prices 3.57M shares at $1.68 in registered direct offering

NanoViricides Inc. Launches Private Placement of Warrants in $6 Million Deal

NanoViricides receives approval to start Phase II trial of NV-387

NanoViricides Wins DRC Approval to Begin Phase II Trial of NV-387 for MPox

NanoViricides Inc. to Present at Spartan Capital Investor Conference in New York City

NanoViricides Announces NV-387 Shows Potent Anti-Measles Activity in Phase I Trial

NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies

BRIEF-Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model

NanoViricides: Nv-387 Has Already Completed Phase I Clinical Trial in Healthy Subjects With No Reported Adverse Events

THOMSON REUTERS

NanoViricides: Clinical Lead Drug Nv-387 Has Shown Strong Activity Against Measles Virus in a Humanized Animal Model

THOMSON REUTERS

NanoViricides: Nv-387 Can NOW Be Made Available for Emergency Use Application in Measles Patients to Respond to Spreading Measles Outbreaks

THOMSON REUTERS

NanoViricides Announces Strong Measles Drug Results and Emergency Use Availability

NanoViricides Inc. Announces Date for Upcoming Annual Meeting of Stockholders

NanoViricides Inc. Announces New Compensation Agreements, Extends President Dr. Anil Diwan’s Contract with $400,000 Salary and Equity Incentives

Nanoviricides Q4 EPS $(0.13) Up From $(0.19) YoY

NanoViricides Reports No Revenue for Fiscal Year Ended June 30, 2025; Net Loss Continues as R&D Expenses Rise by $112,000

NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease

NanoViricides Inc. Advances NV-387 into Phase II Clinical Trials for Potential Cancer Resurgence and Viral Infection Treatment

NanoViricides Inc. Announces Promising Results for NV-387 in Combatting Global Measles Outbreaks, Seeks Accelerated FDA Approval

NanoViricides Inc. Announces Breakthrough in Measles Treatment with Successful NV-387 Animal Trials

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NNVC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NNVC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NNVC\",,,,,undefined,":{"symbol":"NNVC","market":"US","secType":"STK","nameCN":"NanoViricides","latestPrice":1.59,"timestamp":1762894800000,"preClose":1.68,"halted":0,"volume":399676,"delay":0,"floatShares":16863700,"shares":17431000,"eps":-0.626265,"marketStatus":"Pre-Mkt","change":-0.09,"latestTime":"11-12 07:47:08 EST","open":1.61,"high":1.676,"low":1.55,"amount":641522.5055263999,"amplitude":0.075,"askPrice":1.64,"askSize":1219,"bidPrice":1.58,"bidSize":2265,"shortable":3,"etf":0,"ttmEps":-0.626265,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1762957800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1380081600000,"exchange":"AMEX","adjPreClose":1.59,"postHourTrading":{"tag":"盘后","latestPrice":1.55,"preClose":1.59,"latestTime":"19:46 EST","volume":869,"amount":1363.1189,"timestamp":1762908369828},"volumeRatio":0.6642139518346822,"impliedVol":1.563,"impliedVolPercentile":0.8072},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NNVC\",,,,,undefined,":{"symbol":"NNVC","floatShares":16863700,"roa":"-55.39%","roe":"-99.75%","lyrEps":-0.626265,"volumeRatio":0.6642139518346822,"shares":17431000,"dividePrice":0,"high":1.676,"amplitude":0.075,"preClose":1.68,"low":1.55,"week52Low":0.94,"pbRate":"3.69","week52High":2.2299,"institutionHeld":0,"latestPrice":1.59,"committee":0.30023,"eps":-0.626265,"divideRate":0,"volume":399676,"delay":0,"ttmEps":-0.626265,"open":1.61,"prevYearClose":1.43,"prevWeekClose":1.84,"prevMonthClose":1.66,"prevQuarterClose":1.43,"fiveDayClose":1.91,"twentyDayClose":1.35,"sixtyDayClose":1.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NNVC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-09-29","symbol":"NNVC","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1759118400000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2025-05-15","symbol":"NNVC","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2025-02-14","symbol":"NNVC","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739509200000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2024-11-14","symbol":"NNVC","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.23},{"market":"US","date":"2024-09-27","symbol":"NNVC","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1727409600000,"reportTimeType":"post","actualEps":-0.19}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NNVC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NNVC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NNVC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NNVC","date":"2025-11-11","current":-2.538861,"percent":0.220758,"low":-8.257983,"twenty":-3.254271,"median":-2.395993,"eighty":-2.020561,"high":-1.333135,"avg":-2.813481,"sd":1.251703,"marketCap":29284080},"quantilePoints":[{"date":"2020-11-13","current":-2.778824,"twenty":-11.551315,"median":-5.646071,"eighty":-2.576332,"marketCap":37365564},{"date":"2020-11-20","current":-2.817128,"twenty":-11.551315,"median":-5.55316,"eighty":-2.576332,"marketCap":39993750},{"date":"2020-11-27","current":-2.704443,"twenty":-11.551315,"median":-5.550142,"eighty":-2.576332,"marketCap":38394000},{"date":"2020-12-04","current":-2.907276,"twenty":-11.551315,"median":-5.479283,"eighty":-2.576332,"marketCap":41273550},{"date":"2020-12-11","current":-2.606783,"twenty":-11.551315,"median":-5.436362,"eighty":-2.576332,"marketCap":37007550},{"date":"2020-12-18","current":-2.636832,"twenty":-11.551315,"median":-5.410581,"eighty":-2.576332,"marketCap":37434150},{"date":"2020-12-24","current":-2.636832,"twenty":-11.551315,"median":-5.369111,"eighty":-2.576332,"marketCap":37434150},{"date":"2020-12-31","current":-2.156042,"twenty":-11.481307,"median":-5.329042,"eighty":-2.551389,"marketCap":30608550},{"date":"2021-01-08","current":-2.464048,"twenty":-11.481307,"median":-5.269538,"eighty":-2.537233,"marketCap":34981200},{"date":"2021-01-15","current":-2.464048,"twenty":-11.481307,"median":-5.232807,"eighty":-2.519791,"marketCap":34981200},{"date":"2021-01-22","current":-3.327968,"twenty":-11.481307,"median":-5.222018,"eighty":-2.519791,"marketCap":47245950},{"date":"2021-01-29","current":-3.034986,"twenty":-11.481307,"median":-5.155523,"eighty":-2.519791,"marketCap":43086600},{"date":"2021-02-05","current":-3.538313,"twenty":-11.4113,"median":-5.109511,"eighty":-2.519791,"marketCap":50232150},{"date":"2021-02-12","current":-3.78622,"twenty":-11.341292,"median":-5.07155,"eighty":-2.519791,"marketCap":53751600},{"date":"2021-02-19","current":-3.620149,"twenty":-11.311529,"median":-5.024525,"eighty":-2.519791,"marketCap":52851150},{"date":"2021-02-26","current":-3.057014,"twenty":-11.271284,"median":-5.00388,"eighty":-2.519791,"marketCap":44629860},{"date":"2021-03-05","current":-3.876119,"twenty":-11.177066,"median":-4.973773,"eighty":-2.518657,"marketCap":56588100},{"date":"2021-03-12","current":-3.817611,"twenty":-11.075262,"median":-4.952574,"eighty":-2.518657,"marketCap":55733940},{"date":"2021-03-19","current":-3.678656,"twenty":-10.947439,"median":-4.928766,"eighty":-2.518657,"marketCap":53705310},{"date":"2021-03-26","current":-3.605522,"twenty":-10.921244,"median":-4.89353,"eighty":-2.519791,"marketCap":52637610},{"date":"2021-04-01","current":-3.47388,"twenty":-10.851236,"median":-4.872521,"eighty":-2.519791,"marketCap":50715750},{"date":"2021-04-09","current":-3.408059,"twenty":-10.781228,"median":-4.831249,"eighty":-2.518657,"marketCap":49754820},{"date":"2021-04-16","current":-3.00582,"twenty":-10.596948,"median":-4.785979,"eighty":-2.518657,"marketCap":43882470},{"date":"2021-04-23","current":-3.057014,"twenty":-10.508695,"median":-4.726099,"eighty":-2.518657,"marketCap":44629860},{"date":"2021-04-30","current":-3.035074,"twenty":-10.404778,"median":-4.666105,"eighty":-2.518657,"marketCap":44309550},{"date":"2021-05-07","current":-2.654776,"twenty":-9.700722,"median":-4.544321,"eighty":-2.518657,"marketCap":38757510},{"date":"2021-05-14","current":-4.562569,"twenty":-9.419194,"median":-4.510132,"eighty":-2.506117,"marketCap":39347100},{"date":"2021-05-21","current":-4.776022,"twenty":-9.231528,"median":-4.510132,"eighty":-2.506117,"marketCap":41187900},{"date":"2021-05-28","current":-4.789363,"twenty":-9.074029,"median":-4.510132,"eighty":-2.506117,"marketCap":41302950},{"date":"2021-06-04","current":-5.002817,"twenty":-9.026854,"median":-4.518582,"eighty":-2.509122,"marketCap":43143750},{"date":"2021-06-11","current":-5.883312,"twenty":-8.963729,"median":-4.518582,"eighty":-2.509122,"marketCap":50737050},{"date":"2021-06-18","current":-5.082862,"twenty":-8.899973,"median":-4.518582,"eighty":-2.509122,"marketCap":43834050},{"date":"2021-06-25","current":-6.216833,"twenty":-8.83748,"median":-4.518582,"eighty":-2.509122,"marketCap":53613300},{"date":"2021-07-02","current":-5.736563,"twenty":-8.774355,"median":-4.518582,"eighty":-2.509122,"marketCap":49471500},{"date":"2021-07-09","current":-5.576473,"twenty":-8.71123,"median":-4.518582,"eighty":-2.509122,"marketCap":48090900},{"date":"2021-07-16","current":-5.242952,"twenty":-8.71123,"median":-4.518582,"eighty":-2.509122,"marketCap":45214650},{"date":"2021-07-23","current":-5.656518,"twenty":-8.672078,"median":-4.518582,"eighty":-2.509122,"marketCap":48781200},{"date":"2021-07-30","current":-5.363019,"twenty":-8.648105,"median":-4.518582,"eighty":-2.509122,"marketCap":46250100},{"date":"2021-08-06","current":-5.21627,"twenty":-8.605807,"median":-4.518582,"eighty":-2.509122,"marketCap":44984550},{"date":"2021-08-13","current":-5.069521,"twenty":-8.58498,"median":-4.518582,"eighty":-2.509122,"marketCap":43719000},{"date":"2021-08-20","current":-4.949453,"twenty":-8.521855,"median":-4.518582,"eighty":-2.509122,"marketCap":42683550},{"date":"2021-08-27","current":-5.136225,"twenty":-8.381184,"median":-4.527033,"eighty":-2.509122,"marketCap":44294250},{"date":"2021-09-03","current":-5.363019,"twenty":-8.332481,"median":-4.527335,"eighty":-2.509122,"marketCap":46250100},{"date":"2021-09-10","current":-5.256293,"twenty":-8.269356,"median":-4.527335,"eighty":-2.509122,"marketCap":45329700},{"date":"2021-09-17","current":-5.363019,"twenty":-8.206231,"median":-4.527335,"eighty":-2.509122,"marketCap":46250100},{"date":"2021-09-24","current":-6.777149,"twenty":-8.180981,"median":-4.527335,"eighty":-2.509122,"marketCap":58445400},{"date":"2021-10-01","current":-5.869971,"twenty":-8.079981,"median":-4.527335,"eighty":-2.509122,"marketCap":50622000},{"date":"2021-10-08","current":-5.829949,"twenty":-8.016857,"median":-4.527335,"eighty":-2.509122,"marketCap":50276850},{"date":"2021-10-15","current":-6.36953,"twenty":-8.010675,"median":-4.527335,"eighty":-2.509122,"marketCap":56193200},{"date":"2021-10-22","current":-6.304269,"twenty":-7.953732,"median":-4.527335,"eighty":-2.509122,"marketCap":55617450},{"date":"2021-10-29","current":-6.186798,"twenty":-7.94329,"median":-4.527335,"eighty":-2.509122,"marketCap":54581100},{"date":"2021-11-05","current":-6.173746,"twenty":-7.890607,"median":-4.527335,"eighty":-2.509122,"marketCap":54465950},{"date":"2021-11-12","current":-6.095432,"twenty":-7.788302,"median":-4.527335,"eighty":-2.509122,"marketCap":53775050},{"date":"2021-11-19","current":-5.797853,"twenty":-7.663997,"median":-4.527335,"eighty":-2.509122,"marketCap":52899750},{"date":"2021-11-26","current":-6.138903,"twenty":-7.585674,"median":-4.527335,"eighty":-2.509122,"marketCap":56011500},{"date":"2021-12-03","current":-5.633644,"twenty":-7.428051,"median":-4.527335,"eighty":-2.509122,"marketCap":51401500},{"date":"2021-12-10","current":-5.406277,"twenty":-7.300703,"median":-4.527335,"eighty":-2.509122,"marketCap":49327000},{"date":"2021-12-17","current":-5.229436,"twenty":-7.180968,"median":-4.527335,"eighty":-2.509122,"marketCap":47713500},{"date":"2021-12-23","current":-4.976806,"twenty":-7.079181,"median":-4.527335,"eighty":-2.509122,"marketCap":45408500},{"date":"2021-12-31","current":-4.698914,"twenty":-6.987904,"median":-4.527335,"eighty":-2.509122,"marketCap":42873000},{"date":"2022-01-07","current":-3.890498,"twenty":-6.926651,"median":-4.436412,"eighty":-2.509122,"marketCap":35497000},{"date":"2022-01-14","current":-3.675763,"twenty":-6.89782,"median":-4.401483,"eighty":-2.509122,"marketCap":33537750},{"date":"2022-01-21","current":-2.905242,"twenty":-6.846702,"median":-4.310739,"eighty":-2.509122,"marketCap":26507500},{"date":"2022-01-28","current":-2.728401,"twenty":-6.779582,"median":-4.173405,"eighty":-2.509122,"marketCap":24894000},{"date":"2022-02-04","current":-3.05682,"twenty":-6.712109,"median":-4.02803,"eighty":-2.509122,"marketCap":27890500},{"date":"2022-02-11","current":-2.854716,"twenty":-6.637806,"median":-3.995999,"eighty":-2.509122,"marketCap":26046500},{"date":"2022-02-18","current":-2.62043,"twenty":-6.580578,"median":-3.946834,"eighty":-2.509122,"marketCap":22837320},{"date":"2022-02-25","current":-2.646899,"twenty":-6.52606,"median":-3.923893,"eighty":-2.509122,"marketCap":23068000},{"date":"2022-03-04","current":-2.50132,"twenty":-6.496806,"median":-3.868397,"eighty":-2.507562,"marketCap":21799260},{"date":"2022-03-11","current":-2.448382,"twenty":-6.462701,"median":-3.821268,"eighty":-2.492597,"marketCap":21337900},{"date":"2022-03-18","current":-2.964527,"twenty":-6.435992,"median":-3.787617,"eighty":-2.484025,"marketCap":25836160},{"date":"2022-03-25","current":-3.096872,"twenty":-6.399341,"median":-3.766488,"eighty":-2.484025,"marketCap":26989560},{"date":"2022-04-01","current":-2.73954,"twenty":-6.395635,"median":-3.735019,"eighty":-2.484025,"marketCap":23875380},{"date":"2022-04-08","current":-2.593961,"twenty":-6.356646,"median":-3.703835,"eighty":-2.484025,"marketCap":22606640},{"date":"2022-04-14","current":-2.501584,"twenty":-6.335311,"median":-3.656716,"eighty":-2.482663,"marketCap":21801566},{"date":"2022-04-22","current":-2.223395,"twenty":-6.304269,"median":-3.638432,"eighty":-2.478152,"marketCap":19377120},{"date":"2022-04-29","current":-1.97194,"twenty":-6.279718,"median":-3.579246,"eighty":-2.47116,"marketCap":17185660},{"date":"2022-05-06","current":-1.97194,"twenty":-6.219501,"median":-3.523708,"eighty":-2.460477,"marketCap":17185660},{"date":"2022-05-13","current":-1.710426,"twenty":-6.176384,"median":-3.477537,"eighty":-2.45259,"marketCap":14906541},{"date":"2022-05-20","current":-3.57635,"twenty":-6.112925,"median":-3.448283,"eighty":-2.44683,"marketCap":30040400},{"date":"2022-05-27","current":-2.957366,"twenty":-6.0948,"median":-3.404402,"eighty":-2.44683,"marketCap":24841100},{"date":"2022-06-03","current":-2.751038,"twenty":-6.063146,"median":-3.382022,"eighty":-2.44683,"marketCap":23108000},{"date":"2022-06-10","current":-2.778549,"twenty":-6.021887,"median":-3.36235,"eighty":-2.44683,"marketCap":23339080},{"date":"2022-06-17","current":-2.764793,"twenty":-5.978029,"median":-3.327968,"eighty":-2.44683,"marketCap":23223540},{"date":"2022-06-24","current":-2.806059,"twenty":-5.953332,"median":-3.30945,"eighty":-2.445278,"marketCap":23570160},{"date":"2022-07-01","current":-2.599731,"twenty":-5.898451,"median":-3.23985,"eighty":-2.445278,"marketCap":21837060},{"date":"2022-07-08","current":-3.148563,"twenty":-5.871439,"median":-3.219656,"eighty":-2.445278,"marketCap":26447106},{"date":"2022-07-15","current":-2.737283,"twenty":-5.837732,"median":-3.192745,"eighty":-2.445278,"marketCap":22992460},{"date":"2022-07-22","current":-2.874835,"twenty":-5.807263,"median":-3.167389,"eighty":-2.445278,"marketCap":24147860},{"date":"2022-07-29","current":-2.503445,"twenty":-5.78537,"median":-3.144776,"eighty":-2.440257,"marketCap":21028280},{"date":"2022-08-05","current":-4.869338,"twenty":-5.744619,"median":-3.132647,"eighty":-2.440257,"marketCap":40901160},{"date":"2022-08-12","current":-3.823943,"twenty":-5.727928,"median":-3.132647,"eighty":-2.440257,"marketCap":32120120},{"date":"2022-08-19","current":-3.342511,"twenty":-5.684312,"median":-3.132647,"eighty":-2.440257,"marketCap":28076220},{"date":"2022-08-26","current":-3.094918,"twenty":-5.661854,"median":-3.132245,"eighty":-2.440257,"marketCap":25996500},{"date":"2022-09-02","current":-2.902345,"twenty":-5.581809,"median":-3.128118,"eighty":-2.440257,"marketCap":24378940},{"date":"2022-09-09","current":-2.984876,"twenty":-5.560806,"median":-3.117013,"eighty":-2.440257,"marketCap":25072180},{"date":"2022-09-16","current":-2.668507,"twenty":-5.55316,"median":-3.10436,"eighty":-2.440257,"marketCap":22414760},{"date":"2022-09-23","current":-2.14581,"twenty":-5.519162,"median":-3.095823,"eighty":-2.439684,"marketCap":18024240},{"date":"2022-09-30","current":-2.379648,"twenty":-5.477266,"median":-3.088522,"eighty":-2.439647,"marketCap":19988420},{"date":"2022-10-07","current":-2.132055,"twenty":-5.456405,"median":-3.080603,"eighty":-2.439647,"marketCap":17908700},{"date":"2022-10-14","current":-2.502362,"twenty":-5.43594,"median":-3.072683,"eighty":-2.437394,"marketCap":20286302},{"date":"2022-10-21","current":-2.402267,"twenty":-5.421719,"median":-3.06696,"eighty":-2.434784,"marketCap":19474850},{"date":"2022-10-28","current":-2.359369,"twenty":-5.377446,"median":-3.06013,"eighty":-2.430342,"marketCap":19127085},{"date":"2022-11-04","current":-2.334363,"twenty":-5.363019,"median":-3.057014,"eighty":-2.4206,"marketCap":18924360},{"date":"2022-11-11","current":-2.477575,"twenty":-5.336338,"median":-3.043934,"eighty":-2.417533,"marketCap":20085364},{"date":"2022-11-18","current":-2.711681,"twenty":-5.332826,"median":-3.036058,"eighty":-2.417533,"marketCap":19156500},{"date":"2022-11-25","current":-2.760984,"twenty":-5.332826,"median":-3.034986,"eighty":-2.417533,"marketCap":19504800},{"date":"2022-12-02","current":-2.777419,"twenty":-5.332826,"median":-3.028333,"eighty":-2.417533,"marketCap":19620900},{"date":"2022-12-09","current":-2.39121,"twenty":-5.292381,"median":-3.026142,"eighty":-2.416192,"marketCap":16892550},{"date":"2022-12-16","current":-2.087173,"twenty":-5.292381,"median":-3.018926,"eighty":-2.406742,"marketCap":14744700},{"date":"2022-12-23","current":-1.972132,"twenty":-5.292381,"median":-3.00582,"eighty":-2.395506,"marketCap":13932000},{"date":"2022-12-30","current":-1.824222,"twenty":-5.292381,"median":-2.997432,"eighty":-2.389879,"marketCap":12887100},{"date":"2023-01-06","current":-2.202214,"twenty":-5.277173,"median":-2.989706,"eighty":-2.387968,"marketCap":15557400},{"date":"2023-01-13","current":-2.333853,"twenty":-5.260084,"median":-2.981981,"eighty":-2.376115,"marketCap":16487361},{"date":"2023-01-20","current":-2.30082,"twenty":-5.250996,"median":-2.973783,"eighty":-2.373517,"marketCap":16254000},{"date":"2023-01-27","current":-2.399427,"twenty":-5.240028,"median":-2.96653,"eighty":-2.370947,"marketCap":16950600},{"date":"2023-02-03","current":-2.284386,"twenty":-5.221675,"median":-2.956693,"eighty":-2.366583,"marketCap":16137900},{"date":"2023-02-10","current":-2.276169,"twenty":-5.202929,"median":-2.950137,"eighty":-2.360695,"marketCap":16079850},{"date":"2023-02-17","current":-2.44914,"twenty":-5.171998,"median":-2.943354,"eighty":-2.359369,"marketCap":16870750},{"date":"2023-02-24","current":-2.128219,"twenty":-5.154465,"median":-2.937326,"eighty":-2.348627,"marketCap":14660100},{"date":"2023-03-03","current":-2.330906,"twenty":-5.122989,"median":-2.92765,"eighty":-2.343232,"marketCap":16056300},{"date":"2023-03-10","current":-2.145109,"twenty":-5.087088,"median":-2.913716,"eighty":-2.342061,"marketCap":14776450},{"date":"2023-03-17","current":-2.195781,"twenty":-5.05618,"median":-2.905242,"eighty":-2.334159,"marketCap":15125500},{"date":"2023-03-24","current":-2.094437,"twenty":-5.017952,"median":-2.902345,"eighty":-2.329408,"marketCap":14427400},{"date":"2023-03-31","current":-1.97975,"twenty":-5.017055,"median":-2.891819,"eighty":-2.325041,"marketCap":13637383},{"date":"2023-04-06","current":-2.753172,"twenty":-5.017055,"median":-2.888698,"eighty":-2.322276,"marketCap":18965050},{"date":"2023-04-14","current":-1.993094,"twenty":-5.017952,"median":-2.874835,"eighty":-2.316037,"marketCap":13729300},{"date":"2023-04-21","current":-2.263344,"twenty":-5.002368,"median":-2.859591,"eighty":-2.313801,"marketCap":15590900},{"date":"2023-04-28","current":-2.280234,"twenty":-5.002368,"median":-2.849614,"eighty":-2.312786,"marketCap":15707250},{"date":"2023-05-05","current":-2.077547,"twenty":-5.002368,"median":-2.840873,"eighty":-2.302937,"marketCap":14311050},{"date":"2023-05-11","current":-2.043766,"twenty":-5.002368,"median":-2.835777,"eighty":-2.30082,"marketCap":14078350},{"date":"2023-05-19","current":-1.920317,"twenty":-5.002518,"median":-2.832097,"eighty":-2.294808,"marketCap":13055420},{"date":"2023-05-26","current":-1.887542,"twenty":-5.002667,"median":-2.817128,"eighty":-2.284962,"marketCap":12832600},{"date":"2023-06-02","current":-2.239311,"twenty":-5.002667,"median":-2.810544,"eighty":-2.283362,"marketCap":15224130},{"date":"2023-06-09","current":-1.973339,"twenty":-5.002817,"median":-2.806059,"eighty":-2.276679,"marketCap":13415900},{"date":"2023-06-16","current":-1.870383,"twenty":-5.008153,"median":-2.792391,"eighty":-2.269675,"marketCap":12715940},{"date":"2023-06-23","current":-1.921861,"twenty":-5.010821,"median":-2.779567,"eighty":-2.263344,"marketCap":13065920},{"date":"2023-06-30","current":-2.144934,"twenty":-5.017055,"median":-2.778549,"eighty":-2.263295,"marketCap":14582500},{"date":"2023-07-06","current":-2.024818,"twenty":-5.017952,"median":-2.777419,"eighty":-2.259272,"marketCap":13765880},{"date":"2023-07-14","current":-2.488124,"twenty":-5.020645,"median":-2.769833,"eighty":-2.254292,"marketCap":16915700},{"date":"2023-07-21","current":-2.745516,"twenty":-5.0361,"median":-2.767019,"eighty":-2.252684,"marketCap":18665600},{"date":"2023-07-27","current":-2.676878,"twenty":-5.039964,"median":-2.764793,"eighty":-2.252282,"marketCap":18198960},{"date":"2023-08-04","current":-2.453805,"twenty":-5.039964,"median":-2.753964,"eighty":-2.252129,"marketCap":16682380},{"date":"2023-08-11","current":-2.219738,"twenty":-5.039964,"median":-2.751307,"eighty":-2.246058,"marketCap":15091061},{"date":"2023-08-18","current":-2.21991,"twenty":-5.039964,"median":-2.751307,"eighty":-2.244476,"marketCap":15092230},{"date":"2023-08-25","current":-2.667127,"twenty":-5.039964,"median":-2.753168,"eighty":-2.251186,"marketCap":18132670},{"date":"2023-09-01","current":-2.495054,"twenty":-5.039964,"median":-2.751038,"eighty":-2.251186,"marketCap":16962820},{"date":"2023-09-08","current":-2.340189,"twenty":-5.039964,"median":-2.74376,"eighty":-2.251186,"marketCap":15909955},{"date":"2023-09-15","current":-2.288567,"twenty":-5.039964,"median":-2.738088,"eighty":-2.246453,"marketCap":15559001},{"date":"2023-09-22","current":-2.185324,"twenty":-5.039964,"median":-2.725967,"eighty":-2.236945,"marketCap":14857091},{"date":"2023-09-29","current":-2.426225,"twenty":-5.039964,"median":-2.723609,"eighty":-2.236573,"marketCap":16494880},{"date":"2023-10-06","current":-2.254153,"twenty":-5.039964,"median":-2.723609,"eighty":-2.234464,"marketCap":15325031},{"date":"2023-10-13","current":-2.013251,"twenty":-5.039964,"median":-2.723467,"eighty":-2.230216,"marketCap":13687241},{"date":"2023-10-20","current":-1.572776,"twenty":-5.039964,"median":-2.723467,"eighty":-2.222732,"marketCap":13507900},{"date":"2023-10-27","current":-1.600128,"twenty":-5.039964,"median":-2.72369,"eighty":-2.219772,"marketCap":13742820},{"date":"2023-11-03","current":-1.5591,"twenty":-5.039964,"median":-2.72369,"eighty":-2.211571,"marketCap":13390440},{"date":"2023-11-10","current":-1.463365,"twenty":-5.039964,"median":-2.718749,"eighty":-2.202243,"marketCap":12568220},{"date":"2023-11-17","current":-1.487026,"twenty":-5.039964,"median":-2.715489,"eighty":-2.195907,"marketCap":13363424},{"date":"2023-11-24","current":-1.359275,"twenty":-5.039964,"median":-2.713071,"eighty":-2.189723,"marketCap":12215368},{"date":"2023-12-01","current":-1.503045,"twenty":-5.039964,"median":-2.709773,"eighty":-2.185324,"marketCap":13507379},{"date":"2023-12-08","current":-1.50958,"twenty":-5.039964,"median":-2.70214,"eighty":-2.168223,"marketCap":13566106},{"date":"2023-12-15","current":-1.489975,"twenty":-5.039964,"median":-2.696474,"eighty":-2.162,"marketCap":13389923},{"date":"2023-12-22","current":-1.385415,"twenty":-5.039964,"median":-2.696474,"eighty":-2.156514,"marketCap":12450279},{"date":"2023-12-29","current":-1.398485,"twenty":-5.039964,"median":-2.696931,"eighty":-2.156278,"marketCap":12567735},{"date":"2024-01-05","current":-1.424625,"twenty":-5.039964,"median":-2.698293,"eighty":-2.150909,"marketCap":12802646},{"date":"2024-01-12","current":-1.353525,"twenty":-5.039964,"median":-2.698293,"eighty":-2.145109,"marketCap":12163688},{"date":"2024-01-19","current":-1.359275,"twenty":-5.043083,"median":-2.699655,"eighty":-2.135592,"marketCap":12215368},{"date":"2024-01-26","current":-1.385415,"twenty":-5.039964,"median":-2.698293,"eighty":-2.120042,"marketCap":12450279},{"date":"2024-02-02","current":-1.476905,"twenty":-5.039964,"median":-2.698293,"eighty":-2.111328,"marketCap":13272468},{"date":"2024-02-09","current":-1.516115,"twenty":-5.039964,"median":-2.687524,"eighty":-2.094437,"marketCap":13624834},{"date":"2024-02-16","current":-1.498107,"twenty":-5.039964,"median":-2.682084,"eighty":-2.081184,"marketCap":14017010},{"date":"2024-02-23","current":-1.59882,"twenty":-5.039964,"median":-2.676392,"eighty":-2.064581,"marketCap":14959330},{"date":"2024-03-01","current":-1.699533,"twenty":-5.0361,"median":-2.668507,"eighty":-2.049674,"marketCap":15901650},{"date":"2024-03-08","current":-1.422572,"twenty":-5.0361,"median":-2.666881,"eighty":-2.03312,"marketCap":13310270},{"date":"2024-03-15","current":-1.472929,"twenty":-5.0361,"median":-2.656354,"eighty":-2.014962,"marketCap":13781430},{"date":"2024-03-22","current":-1.435162,"twenty":-5.0361,"median":-2.651857,"eighty":-1.997134,"marketCap":13428060},{"date":"2024-03-28","current":-1.422572,"twenty":-5.0361,"median":-2.646899,"eighty":-1.988953,"marketCap":13310270},{"date":"2024-04-05","current":-1.724712,"twenty":-5.039964,"median":-2.645782,"eighty":-1.976203,"marketCap":16137230},{"date":"2024-04-12","current":-1.59882,"twenty":-5.039964,"median":-2.640997,"eighty":-1.967997,"marketCap":14959330},{"date":"2024-04-19","current":-1.479223,"twenty":-5.039964,"median":-2.636576,"eighty":-1.942422,"marketCap":13840325},{"date":"2024-04-26","current":-1.397394,"twenty":-5.0361,"median":-2.625126,"eighty":-1.921861,"marketCap":13074690},{"date":"2024-05-03","current":-1.510696,"twenty":-5.0361,"median":-2.62043,"eighty":-1.908491,"marketCap":14134800},{"date":"2024-05-10","current":-2.303812,"twenty":-5.0361,"median":-2.62043,"eighty":-1.904702,"marketCap":21555570},{"date":"2024-05-17","current":-2.762595,"twenty":-5.0361,"median":-2.63632,"eighty":-1.904702,"marketCap":26267170},{"date":"2024-05-24","current":-2.762595,"twenty":-5.0361,"median":-2.640997,"eighty":-1.904702,"marketCap":26267170},{"date":"2024-05-31","current":-3.010361,"twenty":-5.0361,"median":-2.645943,"eighty":-1.904702,"marketCap":28622970},{"date":"2024-06-07","current":-3.282904,"twenty":-5.0361,"median":-2.651857,"eighty":-1.904702,"marketCap":31214350},{"date":"2024-06-14","current":-3.205683,"twenty":-5.039964,"median":-2.663299,"eighty":-1.904702,"marketCap":30480120},{"date":"2024-06-21","current":-2.522301,"twenty":-5.039964,"median":-2.666881,"eighty":-1.904582,"marketCap":23982420},{"date":"2024-06-28","current":-2.149547,"twenty":-5.039964,"median":-2.667004,"eighty":-1.904221,"marketCap":20438220},{"date":"2024-07-05","current":-2.186822,"twenty":-5.039964,"median":-2.667004,"eighty":-1.904221,"marketCap":20792640},{"date":"2024-07-12","current":-2.236523,"twenty":-5.039964,"median":-2.667004,"eighty":-1.904221,"marketCap":21265200},{"date":"2024-07-15","current":-2.161972,"twenty":-5.039964,"median":-2.667004,"eighty":-1.904221,"marketCap":20556360},{"date":"2024-08-02","current":-2.609277,"twenty":-5.05618,"median":-2.674394,"eighty":-1.887542,"marketCap":24809400},{"date":"2024-08-09","current":-2.360774,"twenty":-5.05618,"median":-2.674394,"eighty":-1.887542,"marketCap":22446600},{"date":"2024-08-16","current":-2.360774,"twenty":-5.05618,"median":-2.674394,"eighty":-1.887542,"marketCap":22446600},{"date":"2024-08-23","current":-2.286223,"twenty":-5.05618,"median":-2.675731,"eighty":-1.887542,"marketCap":21737760},{"date":"2024-08-30","current":-2.335924,"twenty":-5.05618,"median":-2.675731,"eighty":-1.890067,"marketCap":22210320},{"date":"2024-09-06","current":-2.224098,"twenty":-5.05618,"median":-2.675731,"eighty":-1.890067,"marketCap":21147060},{"date":"2024-09-13","current":-2.087421,"twenty":-5.05618,"median":-2.675731,"eighty":-1.899521,"marketCap":19847520},{"date":"2024-09-20","current":-1.96317,"twenty":-5.05618,"median":-2.675731,"eighty":-1.917578,"marketCap":18666120},{"date":"2024-09-27","current":-1.764368,"twenty":-5.05618,"median":-2.675731,"eighty":-1.921243,"marketCap":16775880},{"date":"2024-10-04","current":-2.008373,"twenty":-5.05618,"median":-2.675731,"eighty":-1.947416,"marketCap":16657740},{"date":"2024-10-11","current":-1.951398,"twenty":-5.05618,"median":-2.675731,"eighty":-1.961627,"marketCap":16185180},{"date":"2024-10-18","current":-2.122323,"twenty":-5.05618,"median":-2.675731,"eighty":-1.972856,"marketCap":17602860},{"date":"2024-10-25","current":-2.122323,"twenty":-5.05618,"median":-2.675731,"eighty":-1.978331,"marketCap":17602860},{"date":"2024-10-31","current":-1.937154,"twenty":-5.05618,"median":-2.675731,"eighty":-1.988348,"marketCap":16067040},{"date":"2024-11-08","current":-2.122323,"twenty":-5.05618,"median":-2.675818,"eighty":-2.003331,"marketCap":17602860},{"date":"2024-11-15","current":-1.908667,"twenty":-5.05618,"median":-2.675818,"eighty":-2.007658,"marketCap":15830760},{"date":"2024-11-22","current":-1.599829,"twenty":-5.05618,"median":-2.675818,"eighty":-2.007658,"marketCap":15121920},{"date":"2024-11-29","current":-2.06427,"twenty":-5.05618,"median":-2.675818,"eighty":-2.022617,"marketCap":19511920},{"date":"2024-12-06","current":-2.216055,"twenty":-5.05618,"median":-2.675818,"eighty":-2.028308,"marketCap":20946620},{"date":"2024-12-13","current":-2.231234,"twenty":-5.05618,"median":-2.675818,"eighty":-2.043766,"marketCap":21090090},{"date":"2024-12-20","current":-2.200877,"twenty":-5.05618,"median":-2.675818,"eighty":-2.051201,"marketCap":20803150},{"date":"2024-12-27","current":-2.291947,"twenty":-5.05618,"median":-2.675818,"eighty":-2.063251,"marketCap":21663970},{"date":"2025-01-03","current":-2.155341,"twenty":-5.05618,"median":-2.675818,"eighty":-2.067504,"marketCap":20372740},{"date":"2025-01-10","current":-2.109806,"twenty":-5.05618,"median":-2.675905,"eighty":-2.079813,"marketCap":19942330},{"date":"2025-01-17","current":-1.821415,"twenty":-5.05618,"median":-2.675905,"eighty":-2.079813,"marketCap":17216400},{"date":"2025-01-24","current":-1.699987,"twenty":-5.05618,"median":-2.675731,"eighty":-2.077956,"marketCap":16068640},{"date":"2025-01-31","current":-1.624095,"twenty":-5.019747,"median":-2.668507,"eighty":-2.064332,"marketCap":15351290},{"date":"2025-02-07","current":-1.86695,"twenty":-4.974978,"median":-2.666881,"eighty":-2.051347,"marketCap":17646810},{"date":"2025-02-14","current":-1.958021,"twenty":-4.948211,"median":-2.651857,"eighty":-2.049178,"marketCap":18507630},{"date":"2025-02-21","current":-2.42188,"twenty":-4.923399,"median":-2.645943,"eighty":-2.049178,"marketCap":22680335},{"date":"2025-02-28","current":-2.238151,"twenty":-4.869408,"median":-2.636832,"eighty":-2.049178,"marketCap":20959758},{"date":"2025-03-07","current":-2.204746,"twenty":-4.859238,"median":-2.619088,"eighty":-2.043766,"marketCap":20646926},{"date":"2025-03-14","current":-2.021017,"twenty":-4.814317,"median":-2.611175,"eighty":-2.043766,"marketCap":18926349},{"date":"2025-03-21","current":-2.204746,"twenty":-4.762681,"median":-2.603257,"eighty":-2.043766,"marketCap":20646926},{"date":"2025-03-28","current":-2.021017,"twenty":-4.736,"median":-2.593961,"eighty":-2.037721,"marketCap":18926349},{"date":"2025-04-04","current":-1.904099,"twenty":-4.695977,"median":-2.574477,"eighty":-2.024878,"marketCap":17831436},{"date":"2025-04-11","current":-1.78718,"twenty":-4.601221,"median":-2.559576,"eighty":-2.021017,"marketCap":16736523},{"date":"2025-04-17","current":-2.338367,"twenty":-4.561033,"median":-2.554258,"eighty":-2.021017,"marketCap":21898255},{"date":"2025-04-25","current":-2.254854,"twenty":-4.395718,"median":-2.539152,"eighty":-2.021017,"marketCap":21116174},{"date":"2025-05-02","current":-2.221448,"twenty":-4.236599,"median":-2.517715,"eighty":-2.021017,"marketCap":20803342},{"date":"2025-05-09","current":-2.355069,"twenty":-4.022387,"median":-2.509122,"eighty":-2.021017,"marketCap":22054671},{"date":"2025-05-16","current":-2.188043,"twenty":-3.94774,"median":-2.501973,"eighty":-2.021017,"marketCap":20490510},{"date":"2025-05-23","current":-2.379913,"twenty":-3.876119,"median":-2.498632,"eighty":-2.021017,"marketCap":23149584},{"date":"2025-05-30","current":-2.524637,"twenty":-3.823943,"median":-2.498632,"eighty":-2.021017,"marketCap":24557329},{"date":"2025-06-06","current":-2.395993,"twenty":-3.78622,"median":-2.493989,"eighty":-2.021017,"marketCap":23306000},{"date":"2025-06-13","current":-2.494967,"twenty":-3.754515,"median":-2.493989,"eighty":-2.021017,"marketCap":24268720},{"date":"2025-06-20","current":-2.214076,"twenty":-3.676342,"median":-2.479073,"eighty":-2.020561,"marketCap":21536480},{"date":"2025-06-27","current":-2.032324,"twenty":-3.636238,"median":-2.464048,"eighty":-2.020561,"marketCap":19768560},{"date":"2025-07-03","current":-2.280168,"twenty":-3.554341,"median":-2.459464,"eighty":-2.020561,"marketCap":22179360},{"date":"2025-07-11","current":-2.329737,"twenty":-3.48487,"median":-2.44873,"eighty":-2.020561,"marketCap":22661520},{"date":"2025-07-18","current":-2.709765,"twenty":-3.426034,"median":-2.448382,"eighty":-2.020561,"marketCap":26358080},{"date":"2025-07-25","current":-2.825426,"twenty":-3.389044,"median":-2.448382,"eighty":-2.020561,"marketCap":27483120},{"date":"2025-08-01","current":-2.676719,"twenty":-3.365641,"median":-2.448382,"eighty":-2.020561,"marketCap":26036640},{"date":"2025-08-08","current":-2.610627,"twenty":-3.332199,"median":-2.448382,"eighty":-2.020561,"marketCap":25393760},{"date":"2025-08-15","current":-2.428875,"twenty":-3.310157,"median":-2.445165,"eighty":-2.020561,"marketCap":23625840},{"date":"2025-08-22","current":-2.263645,"twenty":-3.264565,"median":-2.436645,"eighty":-2.020561,"marketCap":22018640},{"date":"2025-08-29","current":-2.337999,"twenty":-3.264565,"median":-2.434612,"eighty":-2.020561,"marketCap":22741880},{"date":"2025-09-05","current":-2.271907,"twenty":-3.248873,"median":-2.421397,"eighty":-2.020104,"marketCap":22099000},{"date":"2025-09-12","current":-2.362783,"twenty":-3.247549,"median":-2.416566,"eighty":-2.020561,"marketCap":22982960},{"date":"2025-09-19","current":-2.34626,"twenty":-3.208752,"median":-2.407158,"eighty":-2.020561,"marketCap":22822240},{"date":"2025-09-26","current":-2.313214,"twenty":-3.208752,"median":-2.402267,"eighty":-2.020561,"marketCap":22500800},{"date":"2025-10-03","current":-2.63298,"twenty":-3.208752,"median":-2.395993,"eighty":-2.020561,"marketCap":24926330},{"date":"2025-10-10","current":-2.623774,"twenty":-3.208752,"median":-2.395993,"eighty":-2.020561,"marketCap":24839175},{"date":"2025-10-17","current":-2.669805,"twenty":-3.208752,"median":-2.395993,"eighty":-2.020561,"marketCap":25274950},{"date":"2025-10-24","current":-2.636294,"twenty":-3.208752,"median":-2.395993,"eighty":-2.020561,"marketCap":24957705},{"date":"2025-10-31","current":-3.130116,"twenty":-3.221382,"median":-2.395993,"eighty":-2.020561,"marketCap":29632700},{"date":"2025-11-07","current":-3.498365,"twenty":-3.252844,"median":-2.395993,"eighty":-2.020561,"marketCap":33118900},{"date":"2025-11-11","current":-3.093291,"twenty":-3.254271,"median":-2.395993,"eighty":-2.020561,"marketCap":29284080}],"updateTime":1762940816719},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NNVC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582628953","title":"NanoViricides prices 3.57M shares at $1.68 in registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2582628953","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582628953?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:45","pubTimestamp":1762868742,"startTime":"0","endTime":"0","summary":"NanoViricides (NNVC) entered into a securities purchase agreement with a single healthcare institutional investor for the purchase and sale of 3,57...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nanoviricides-prices-3-57m-shares-at-1-68-in-registered-direct-offering-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nanoviricides-prices-3-57m-shares-at-1-68-in-registered-direct-offering-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0},{"id":"2582361006","title":"NanoViricides Inc. Launches Private Placement of Warrants in $6 Million Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2582361006","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582361006?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:30","pubTimestamp":1762867825,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. has announced a concurrent private placement alongside its registered direct offering, issuing Series A and Series B warrants to purchase up to 3,571,429 shares of common stock each. The Series A Warrants will have an exercise price of $1.75 per share, exercisable six months after issuance and expiring two years later. The Series B Warrants, with an exercise price of $2.00 per share-about a 20% premium to the prior closing price-become exercisable after six months and expire 5.5 years from issuance. The warrants and the shares underlying them will be sold to an institutional investor in a transaction exempt from SEC registration requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL4BNpyr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC","BK4139","BK4568"],"gpt_icon":0},{"id":"2582877275","title":"NanoViricides receives approval to start Phase II trial of NV-387","url":"https://stock-news.laohu8.com/highlight/detail?id=2582877275","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582877275?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:20","pubTimestamp":1762784458,"startTime":"0","endTime":"0","summary":"NanoViricides (NNVC) has received approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nanoviricides-receives-approval-to-start-phase-ii-trial-of-nv-387-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nanoviricides-receives-approval-to-start-phase-ii-trial-of-nv-387-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NNVC","BK4139","BK4568"],"gpt_icon":0},{"id":"2582091871","title":"NanoViricides Wins DRC Approval to Begin Phase II Trial of NV-387 for MPox","url":"https://stock-news.laohu8.com/highlight/detail?id=2582091871","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582091871?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:31","pubTimestamp":1762781484,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. has received approval from the regulatory agency ACOREP of the Democratic Republic of Congo  to begin a Phase II clinical trial of its antiviral drug candidate, NV-387, for the treatment of MPox. This follows earlier clearance from the DRC's national Ethics Committee, CNES, in May 2025. The company is finalizing and translating the required documentation for submission, after which patient recruitment for the trial can commence. No grant or funding from multiple organizations was announced in this update.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 10, 2025, and is solely responsible for the informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1Vl1g6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","NNVC"],"gpt_icon":0},{"id":"2580215297","title":"NanoViricides Inc. to Present at Spartan Capital Investor Conference in New York City","url":"https://stock-news.laohu8.com/highlight/detail?id=2580215297","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580215297?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:30","pubTimestamp":1762176642,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. will present at the Spartan Capital Investor Conference 2025 in New York City on Monday, November 3, 2025. The company will provide an update on its drug pipeline and platform technologies, including NV-387, a broad-spectrum antiviral drug currently in Phase II clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDLpQS61:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC","BK4568","BK4139"],"gpt_icon":0},{"id":"2579906893","title":"NanoViricides Announces NV-387 Shows Potent Anti-Measles Activity in Phase I Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2579906893","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579906893?lang=en_us&edition=fundamental","pubTime":"2025-10-29 20:45","pubTimestamp":1761741919,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. has announced significant progress with its clinical lead drug, NV-387, which has demonstrated potent activity against the Measles virus in both cell culture studies and a humanized animal model. Results from preclinical studies showed that NV-387 treatment extended survival in a lethal Measles infection model by 130%, from 7.4 days in untreated animals to 17 days in treated ones. NV-387 has also completed Phase I human trials, with no reportable adverse events, confirming its safety and tolerability in healthy subjects. The company is now positioned to support emergency use applications of NV-387 for Measles patients under FDA guidelines and is open to Physician's Investigator-Initiated INDs for urgent cases. NV-387 is formulated as oral gummies, offering a potential advantage for patients with Measles-related throat irritation. The drug is also advancing into a Phase II clinical trial for the evaluation of safety and effectiveness in treating MPox. These results ha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDLb6GjyC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","NNVC"],"gpt_icon":0},{"id":"2577936256","title":"NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2577936256","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577936256?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:45","pubTimestamp":1761137122,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. announced that its clinical lead drug, NV-387, has demonstrated strong antiviral activity against the Measles virus in both cell culture studies and a humanized animal model. The company reported that NV-387 treatment led to protection of lung tissue, an important outcome for patients with severe viral infections. According to NanoViricides, NV-387 has completed a Phase I clinical trial in healthy subjects, showing no reportable adverse events and was found to be safe and well tolerated. The company highlighted that NV-387 is a multi-purpose, broad-spectrum antiviral currently being developed for several respiratory viral infections, including RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, MPox, and Smallpox. Results from the studies have already been presented. NanoViricides is seeking additional funding to support further development of NV-387 as a treatment for Measles.Disclaimer: This news brief was created by Public Technologies  using generative artifi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL8lDxP0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NNVC","BK4568"],"gpt_icon":0},{"id":"2577886159","title":"BRIEF-Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2577886159","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577886159?lang=en_us&edition=fundamental","pubTime":"2025-10-21 00:39","pubTimestamp":1760978390,"startTime":"0","endTime":"0","summary":"BRIEF-Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal ModelOct 20 (Reuters) - NanoViricides Inc NNVC.A:NANOVIRICIDES: CLINICAL LEAD DRUG NV-387 HAS SHOWN STRONG ACTI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nFWN3VZ0CI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","NNVC"],"gpt_icon":0},{"id":"2576655628","title":"NanoViricides: Nv-387 Has Already Completed Phase I Clinical Trial in Healthy Subjects With No Reported Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2576655628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576655628?lang=en_us&edition=fundamental","pubTime":"2025-10-20 23:02","pubTimestamp":1760972531,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nFWN3VZ0CI:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NNVC","BK4568"],"gpt_icon":0},{"id":"2576586534","title":"NanoViricides: Clinical Lead Drug Nv-387 Has Shown Strong Activity Against Measles Virus in a Humanized Animal Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2576586534","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576586534?lang=en_us&edition=fundamental","pubTime":"2025-10-20 23:02","pubTimestamp":1760972531,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nFWN3VZ0CI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","NNVC"],"gpt_icon":0},{"id":"2576343865","title":"NanoViricides: Nv-387 Can NOW Be Made Available for Emergency Use Application in Measles Patients to Respond to Spreading Measles Outbreaks","url":"https://stock-news.laohu8.com/highlight/detail?id=2576343865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576343865?lang=en_us&edition=fundamental","pubTime":"2025-10-20 23:02","pubTimestamp":1760972531,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nFWN3VZ0CI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NNVC","BK4568","BK4139"],"gpt_icon":0},{"id":"2576854110","title":"NanoViricides Announces Strong Measles Drug Results and Emergency Use Availability","url":"https://stock-news.laohu8.com/highlight/detail?id=2576854110","media":"Reuters","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576854110?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:45","pubTimestamp":1760964343,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. has announced that its clinical lead drug, NV-387, has demonstrated strong activity against the measles virus in a humanized animal model. According to the company, NV-387 can now be made available for emergency use in measles patients in response to ongoing outbreaks. The drug has completed Phase I clinical trials in healthy subjects with no reported adverse events. In preclinical studies, NV-387 treatment increased survival in animals infected with measles compared to untreated controls and showed no signs of toxicity. The company is supporting physician-initiated applications for emergency use of NV-387 and is currently focused on advancing the drug into Phase II human clinical trials. Results from the animal studies and Phase I trial have already been presented by the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL1Wpp7D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","NNVC"],"gpt_icon":0},{"id":"2573944653","title":"NanoViricides Inc. Announces Date for Upcoming Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2573944653","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573944653?lang=en_us&edition=fundamental","pubTime":"2025-10-08 18:03","pubTimestamp":1759917833,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. has announced that it will hold its Annual Meeting of Stockholders on November 8, 2025, at the Hampton Inn & Suites Stamford in Stamford, Connecticut. During the meeting, shareholders will vote on several key proposals, including the re-election of Anil Diwan as a Class I director for a two-year term, an advisory vote on the compensation of the company's named executive officers, and the ratification and approval of EisnerAmper LLP as the company's independent registered public accounting firm for the 2026 fiscal year. Additionally, shareholders will consider a proposal to adjourn the meeting if necessary to solicit additional proxies, as well as any other business that may properly come before the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDLb366g8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC","BK4568","BK4139"],"gpt_icon":0},{"id":"2572568355","title":"NanoViricides Inc. Announces New Compensation Agreements, Extends President Dr. Anil Diwan’s Contract with $400,000 Salary and Equity Incentives","url":"https://stock-news.laohu8.com/highlight/detail?id=2572568355","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572568355?lang=en_us&edition=fundamental","pubTime":"2025-10-02 05:08","pubTimestamp":1759352929,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. Announces New Compensation Agreements, Extends President Dr. Anil Diwan's Contract with $400,000 Salary and Equity Incentives. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDLzgbgW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","NNVC"],"gpt_icon":0},{"id":"2571652113","title":"Nanoviricides Q4 EPS $(0.13) Up From $(0.19) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2571652113","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571652113?lang=en_us&edition=fundamental","pubTime":"2025-09-30 05:55","pubTimestamp":1759182922,"startTime":"0","endTime":"0","summary":"Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.13) per share. This is a 31.58 percent increase over losses of $(0.19) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/09/47931496/nanoviricides-q4-eps-0-13-up-from-0-19-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nanoviricides Q4 EPS $(0.13) Up From $(0.19) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC"],"gpt_icon":0},{"id":"2571534368","title":"NanoViricides Reports No Revenue for Fiscal Year Ended June 30, 2025; Net Loss Continues as R&D Expenses Rise by $112,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2571534368","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571534368?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:34","pubTimestamp":1759178057,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. reported its financial results for the fiscal year ended June 30, 2025. The biopharmaceutical company reported no revenues for both the current and prior fiscal years. Net losses continued as the company has not commenced revenue-generating operations. Research and development expenses increased to $5.549 million for the year ended June 30, 2025, compared to $5.437 million for the year ended June 30, 2024. The increase of $0.112 million was mainly attributed to higher outside laboratory fees related to the preparation of Phase II clinical trial applications. NanoViricides stated its ongoing focus is on advancing drug candidates through preclinical studies and preparing for future clinical trials, with the goal of developing antiviral therapies using nanomedicine approaches. The company noted the potential for future developments in the antiviral field to impact its business plan and market opportunities.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL5XcdJb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0},{"id":"2566697128","title":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPOX Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2566697128","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566697128?lang=en_us&edition=fundamental","pubTime":"2025-09-09 20:43","pubTimestamp":1757421812,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a clinical-stage company known for developing broad-spectrum antiviral drugs, has announced that it will be presenting updates on its drug pipeline, platform technologies, and new clinical developments at the Life Science Executive Partnering Congress in Boston on September 17, 2025. The presentation will be led by Anil R. Diwan, PhD, President and Executive Chairman of the company. Among the highlights is their most advanced candidate, NV-387, an ultra-broad-spectrum antiviral targeting multiple respiratory human pathogenic viruses. Additionally, the company will discuss its clinical-ready pan-herpesvirus drug candidate, NV-HHV-1, and its anti-HIV drug candidate, NV-HIV-1. These developments will be presented at the event, indicating that the results are yet to be formally disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDLGxgs8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NNVC","BK4568"],"gpt_icon":0},{"id":"2560490741","title":"NanoViricides Inc. Advances NV-387 into Phase II Clinical Trials for Potential Cancer Resurgence and Viral Infection Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2560490741","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560490741?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:30","pubTimestamp":1755520228,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. Advances NV-387 into Phase II Clinical Trials for Potential Cancer Resurgence and Viral Infection Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire  on August 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL3gvhN9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NNVC","BK4568"],"gpt_icon":0},{"id":"2555104117","title":"NanoViricides Inc. Announces Promising Results for NV-387 in Combatting Global Measles Outbreaks, Seeks Accelerated FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2555104117","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555104117?lang=en_us&edition=fundamental","pubTime":"2025-07-30 20:30","pubTimestamp":1753878621,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. Announces Promising Results for NV-387 in Combatting Global Measles Outbreaks, Seeks Accelerated FDA Approval. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire  on July 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL9DmXPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NNVC","BK4568"],"gpt_icon":0},{"id":"2553017473","title":"NanoViricides Inc. Announces Breakthrough in Measles Treatment with Successful NV-387 Animal Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2553017473","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553017473?lang=en_us&edition=fundamental","pubTime":"2025-07-21 18:30","pubTimestamp":1753093823,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a clinical stage company specializing in broad-spectrum antivirals, has announced promising results from their recent animal study involving NV-387, a drug candidate aimed at treating Measles. The study utilized humanized mice to simulate Measles infection, as the virus does not naturally infect mice. NV-387 demonstrated a significant increase in survival rates, extending the average lifespan of infected animals from 7.4 days to 17 days, without any observed toxicity. The drug, designed to mimic cellular features essential for viral binding, showed a dose-dependent improvement in survival. These results indicate NV-387's potential as the first drug to effectively treat Measles, as global cases continue to rise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL2xs61k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC","BK4139","BK4568"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}